One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo
Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 2 weeks compared with placebo (moderate certainty).
2 findings from 1 review
- RR 0.82 [0.66, 1.01]2 studies · 1102 participantsModerate
- RR 0.78 [0.66, 0.92]3 studies · 1611 participantsModerate